Bionano Genomics, INC 10-Q quarterly reports

Bionano Genomics reported a 4% increase in Q1 2026 revenue to $6.7 million, driven by instrument and consumable sales, but continues to face substantial doubt about its ability to continue as a going concern.

Bionano Genomics reported a significant reduction in net loss for Q3 2025, driven by cost-saving initiatives, but acknowledged substantial doubt about its ability to continue as a going concern without further capital.

Bionano Genomics, Inc. reported a reduced net loss for Q2 2025, driven by significant cost-cutting measures, but faces substantial doubt about its ability to continue as a going concern without further capital raises.

Bionano Genomics' Q1 2025 results reveal a revenue decrease due to a strategic shift focusing on existing customers, alongside efforts to manage liquidity and explore strategic alternatives.

Bionano Genomics' Q3 2024 results reflect a strategic shift towards existing customers and cost-cutting measures, impacting revenue and incurring significant impairment charges.

Bionano Genomics' Q2 2024 results show a decrease in revenue and a net loss, alongside significant cost-cutting measures and a strategic review of options.

Bionano Genomics reports a net loss of $31.4 million for the first quarter of 2024, alongside a restructuring plan aimed at reducing operating expenses.